
Patients from the Corrona registry, an independent, observational US registry housing data on patients with rheumatic diseases, were included in Dr Harrold and colleagues’ study if they had received a PsA diagnosis; had initiated therapy with a TNFi (ie, adalimumab, etanercept, golimumab, or infliximab) between October 1, 2002, and March 21, 2013; and were aged ≥18 years.
Advances in contemporary imaging techniques have led to more widespread use of this modality for the management of osteoarthritis (OA). However, in the absence of evidence-based guidelines, imaging is often used in circumstances where it does not change management.
Dr Verstappen and colleagues had previously shown that patients treated within 6 months of symptom onset had improved 10-year outcomes compared with those who were treated later.